Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday

Shares of Viking Therapeutics (VKTX) fell 6% on Tuesday after pharma giant Eli Lilly (LLY) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide). These new vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity. A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is available in a single-dose pen (autoinjector), which is priced at about $1,000 for a month's s ...